NBW Capital LLC lowered its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.3% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 61,206 shares of the specialty pharmaceutical company’s stock after selling 824 shares during the period. NBW Capital LLC owned about 0.21% of Collegium Pharmaceutical worth $766,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. American International Group Inc. grew its position in Collegium Pharmaceutical by 27.8% during the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after acquiring an additional 2,163 shares during the last quarter. Voya Investment Management LLC bought a new stake in Collegium Pharmaceutical during the 2nd quarter worth $125,000. Nationwide Fund Advisors grew its position in Collegium Pharmaceutical by 16.4% during the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after acquiring an additional 1,422 shares during the last quarter. Credit Suisse AG grew its position in Collegium Pharmaceutical by 9.4% during the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after acquiring an additional 1,173 shares during the last quarter. Finally, UBS Group AG grew its position in Collegium Pharmaceutical by 283.2% during the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after acquiring an additional 10,174 shares during the last quarter. 83.04% of the stock is owned by institutional investors.

Shares of Collegium Pharmaceutical, Inc. (NASDAQ COLL) traded up 3.60% during midday trading on Friday, reaching $11.79. The company had a trading volume of 993,394 shares. Collegium Pharmaceutical, Inc. has a one year low of $9.27 and a one year high of $18.67. The company has a 50 day moving average of $10.53 and a 200 day moving average of $10.53. The company’s market capitalization is $348.58 million.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. The business had revenue of $3.56 million for the quarter, compared to the consensus estimate of $4.07 million. Analysts predict that Collegium Pharmaceutical, Inc. will post ($3.00) EPS for the current fiscal year.

A number of brokerages recently weighed in on COLL. Zacks Investment Research lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, July 25th. ValuEngine upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Needham & Company LLC restated a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday. Finally, Jefferies Group LLC restated a “buy” rating and set a $15.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Collegium Pharmaceutical presently has an average rating of “Hold” and a consensus target price of $20.00.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-shares-sold-by-nbw-capital-llc/1618046.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.